Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 9/20 | 0.68 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898278 | 1.00 | YTHDC1 (0.68) | YTHDC1CNR2CDK1PNPADORA2A | |
| SCHEMBL5465713 | 0.88 | P2RX7 (0.56) | YTHDC1ADORA2AHDAC1HDAC2HDAC8 | |
| SCHEMBL30898205 | 0.87 | YTHDC1 (0.72) | YTHDC1CNR2ADORA2AP2RX7 | |
| SCHEMBL5451873 | 0.87 | YTHDC1 (0.72) | YTHDC1CNR2ADORA2AP2RX7 | |
| SCHEMBL5161967 | 0.87 | ADORA2A (0.53) | YTHDC1CNR2CDK1PNPADORA2A | |
| SCHEMBL12537206 | 0.86 | YTHDC1 (0.53) | YTHDC1CNR2HDAC1HDAC2HDAC8 | |
| SCHEMBL22345236 | 0.85 | YTHDC1 (0.56) | YTHDC1HDAC1HDAC2HDAC8P2RX7 | |
| SCHEMBL6272417 | 0.85 | ALDH1A1 (0.66) | PNPADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL2060472 | 0.85 | PDE4A (0.67) | YTHDC1CNR2CDK1PNPADORA2A | |
| SCHEMBL12786350 | 0.85 | YTHDC1 (0.69) | YTHDC1CNR2CDK1PNPADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319694-B2 | Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection | UNIVERZITA PALACKEHO (CZ) | 2025-06-03 | — | — | US | disclosed |
| WO-2024105159-A1 | LIGANDS OF THE M6A-RNA READERS | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| EP-3924353-B1 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | UNIV PALACKEHO (CZ) | 2024-04-24 | — | — | EP | disclosed |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2023-12-14 | — | — | US | disclosed |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2023-12-14 | — | — | US | disclosed |
| US-20220127269-A1 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | UNIVERZITA PALACKEHO (CZ) | 2022-04-28 | — | — | US | disclosed |
| EP-3924353-A1 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | Univerzita Palackého (CZ) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021016263-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020164648-A1 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | UNIVERZITA PALACKEHO (CZ) | 2020-08-20 | — | — | WO | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| US-7255835-B2 | Single pass attenuated total reflection fourier transform infrared microscopy apparatus and method for identifying protein secondary structure, surface charge and binding affinity | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060264448-A1 | Purine derivatives | PFIZER LIMITED | 2006-11-23 | — | — | US | disclosed |
| WO-2006122003-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006117670-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | PFIZER LIMITED (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20060234974-A1 | 2,6-Dihalogeno-8-substituent-purine compound and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1595882-A1 | 2,6-DIHALOGENO-8-SUBSTITUENT-PURINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-11-16 | — | — | EP | disclosed |
| US-5583137-A | Heterocyclic compounds for enhancing antitumor activity | PFIZER INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0626964-A1 | HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993017021-A1 | HETEROCYCLIC COMPOUNDS FOR ENHANCING ANTITUMOR ACTIVITY | PFIZER, INC. (US) | 1993-09-02 | — | — | WO | disclosed |
| US-4278675-A | ADMINISTERING 9-CYCLOHEXYL-9H-ADENINE OR 9-BENZYL-2-N-PROPOXY-9H-ADENINE | BRISTOL-MYERS COMPANY (US) | 1981-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127269-A1 | HETEROCYCLIC NITROGEN-CONTAINING PURINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN NEUROPROTECTION | NME4, NLN, PNP | YTHDC1 2241/4885CNR2 453/4885CDK1 528/4885 |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | TST, TYR, STS | YTHDC1 2401/4885CNR2 3498/4885CDK1 375/4885 |
| US-20060264448-A1 | Purine derivatives | TLR9, TLR7, TLR1 | YTHDC1 1433/4885CNR2 186/4885CDK1 1085/4885 |
| US-20060234974-A1 | 2,6-Dihalogeno-8-substituent-purine compound and process for producing the same | HPRT1, TPMT, NUDT1 | YTHDC1 250/4885CNR2 1210/4885CDK1 1180/4885 |
| US-12319694-B2 | Heterocyclic nitrogen-containing purine derivatives, pharmaceutical preparations containing these derivatives and their use in neuroprotection | NME4, NLN, PNP | YTHDC1 2241/4885CNR2 453/4885CDK1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.